UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

January 28, 2020

Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.

January 28, 2020

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.

January 25, 2020

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.

January 25, 2020

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.

January 24, 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).

January 23, 2020

Sandy W. Wong, MD, discusses treatments in the pipeline for multiple myeloma.

January 23, 2020

Nina Shah, MD, discusses newer treatment options in the frontline and maintenance settings in multiple myeloma. 

January 23, 2020

Sandy Wong, MD, discusses the ongoing research of antibody-drug conjugates in multiple myeloma.

January 23, 2020

Lloyd Damon, MD, discusses the evolution of the treatment paradigm in acute lymphoblastic leukemia.

January 21, 2020

Bita Fakhri, MD, discusses data from several recent trials in chronic lymphocytic leukemia and focused on other regimens moving through the pipeline.

January 21, 2020

Neil Dunavin, MD, MS, discusses frontline treatment in myelofibrosis.

January 21, 2020

Weiyun Z. Ai, MD, PhD, discusses some of the most pivotal advances that have been made in the fields of T-cell lymphoma and Hodgkin lymphoma in recent years.

January 20, 2020

Neil Dunavin, MD, MS, highlights criteria to consider when approaching treatment selection for patients with myelofibrosis and discussed next steps for the field.

January 20, 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.

January 20, 2020

Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.

January 18, 2020

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

January 18, 2020

Sandy Wong, MD, discusses ways to mitigate the toxicities of selinexor in patients with relapsed/refractory multiple myeloma.

January 16, 2020

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

January 14, 2020

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco, and co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the management of first relapse in patients with multiple myeloma.

January 14, 2020

Hope S. Rugo, MD, discusses the impact of margetuximab in patients with HER2-positive metastatic breast cancer who have an F allele versus V allele.